Alexandra Gerlach, Associate Editor

Researchers highlight the critical link between school vaccination rates and measles outbreaks, urging targeted public health strategies to combat misinformation and improve MMR coverage.

Combining tramadol with CYP2D6-inhibiting antidepressants raises seizure risk in older adults, highlighting the need for careful medication management.

Repetitive DNA mimics pathogens, influencing cancer immunity and immunotherapy.

Tramadol provides only limited pain relief while carrying a significant risk of serious adverse effects.

Niraparib combined with standard therapy significantly improves progression-free survival in men with HRR-deficient metastatic castration-sensitive prostate cancer.

Medicaid expansion enhances 5-year cancer survival rates in rural and high-poverty areas, highlighting the importance of financial support for better health outcomes.

Frail patients with multiple myeloma (MM) can safely reduce dexamethasone use, enhancing treatment outcomes without increasing infection risks.

BMS-986446 shows promise as a fast-tracked therapy for early Alzheimer disease, targeting tau protein to alter disease progression.

Research highlights the effectiveness of the albuterol-budesonide combination for ensuring rapid relief and safety in patients with asthma.

New research links oral bacteria and fungi to pancreatic cancer risk, suggesting oral microbiota as potential noninvasive biomarkers for early detection.

Cevostamab shows promise as a post-CAR T therapy for relapsed/refractory multiple myeloma, enhancing MRD-negative responses and improving patient outcomes.

Etentamig shows promise in managing infections for relapsed/refractory multiple myeloma.

Anitocabtagene autoleucel shows impressive efficacy and safety in treating relapsed/refractory multiple myeloma, achieving a 97% overall response rate.

Pharmacists play a crucial role in managing drug interactions and optimizing treatment with CDK4/6 inhibitors for HER2-positive breast cancer patients.

Pharmacists enhance patient care by managing CDK4/6 inhibitors, addressing adverse effects and ensuring effective therapy selection in oncology.

New IMWG/IMS guidelines enhance risk assessment for multiple myeloma, revealing daratumumab's impact on patient outcomes in real-world settings.

New research links rapid CAR T-cell expansion to delayed neurotoxicity in patients with multiple myeloma.

Elranatamab enhances MRD negativity in relapsed/refractory multiple myeloma post idecabtagene vicleucel, promising improved treatment outcomes.

Explore the impact of CDK4/6 inhibitors in HR+/HER2– breast cancer treatment and the essential role of oncology pharmacy practice.

Belantamab mafodotin with bortezomib shows promising survival benefits for lenalidomide-refractory multiple myeloma patients.

Idecabtagene vicleucel shows a lower infection risk than other BCMA therapies for multiple myeloma.

Linvoseltamab combined with carfilzomib shows promising results in treating relapsed/refractory multiple myeloma.

Intravenous immunoglobulin (IVIG) treatment significantly reduces infection rates in multiple myeloma patients receiving BCMA bispecific antibodies, showcasing its clinical benefits.

Teclistamab and other bispecific antibodies enhance multiple myeloma treatment but significantly increase infection risks, necessitating proactive management strategies.

Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.

Travelers face rising infectious disease risks, including measles, chikungunya, chagas disease, and others.

The 2025 International Myeloma Society Annual Meeting unveils crucial updates to IMWG guidelines, enhancing response assessment and treatment strategies for multiple myeloma.

Cutting-edge insights and expert discussions on multiple myeloma will be presented at the 2025 IMS Annual Meeting in Toronto, shaping future treatment standards.